31. Vitiello, G.A.F.; Ferreira, W.A.S.; Cordeiro de Lima, V.C.; Medina, T. da S. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. *Front. Immunol.* **2021**, *12*, 782852. [CrossRef] [PubMed]

32. Zitvogel, L.; Galluzzi, L.; Kepp, O.; Smyth, M.J.; Kroemer, G. Type I interferons in anticancer immunity. *Nat. Rev. Immunol.* **2015**, *15*, 405–414. [CrossRef] [PubMed]

33. Yu, R.; Zhu, B.; Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. *Cell. Mol. Life Sci.* **CMLS** **2022**, *79*, 191. [CrossRef]

34. Rommelaere, J.; Geletneky, K.; Angelova, A.L.; Daeffler, L.; Dinsart, C.; Kiprianova, I.; Schlehofer, J.R.; Raykov, Z. Oncolytic parvoviruses as cancer therapeutics. *Cytokine Growth Factor Rev.* **2010**, *21*, 185–195. [CrossRef] [PubMed]

35. Angelova, A.L.; Geletneky, K.; Nüesch, J.P.F.; Rommelaere, J. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. *Front. Bioeng. Biotechnol.* **2015**, *3*, 55. [CrossRef]

36. Geletneky, K.; Nüesch, J.P.; Angelova, A.; Kiprianova, I.; Rommelaere, J. Double-faceted mechanism of parvoviral oncosuppression. *Curr. Opin. Virol.* **2015**, *13*, 17–24. [CrossRef] [PubMed]

37. Geletneky, K.; Hajda, J.; Angelova, A.L.; Leuchs, B.; Capper, D.; Bartsch, A.J.; Neumann, J.-O.; Schöning, T.; Hüsing, J.; Beelte, B.; et al. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. *Mol. Ther. J. Am. Soc. Gene Ther.* **2017**, *25*, 2620–2634. [CrossRef]

38. Hajda, J.; Leuchs, B.; Angelova, A.L.; Frehtman, V.; Rommelaere, J.; Mertens, M.; Pilz, M.; Kieser, M.; Krebs, O.; Huber, B.; et al. Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and immune cell activity in patients with metastatic pancreatic ductal adenocarcinoma. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2021**, *27*, 5546–5556. [CrossRef]

39. Angelova, A.; Ferreira, T.; Bretscher, C.; Rommelaere, J.; Marchini, A. Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers. *Cancers* **2021**, *13*, 342. [CrossRef]

40. Grekova, S.; Zawatzky, R.; Hörlein, R.; Cziepluch, C.; Mincberg, M.; Davis, C.; Rommelaere, J.; Daeffler, L. Activation of an antiviral response in normal but not transformed mouse cells: A new determinant of minute virus of mice oncotropism. *J. Virol.* **2010**, *84*, 516–531. [CrossRef]

41. Raykov, Z.; Grekova, S.P.; Hörlein, R.; Leuchs, B.; Giese, T.; Giese, N.A.; Rommelaere, J.; Zawatzky, R.; Daeffler, L. TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. *PLoS ONE* **2013**, *8*, 55086. [CrossRef] [PubMed]

42. Raykov, Z.; Grekova, S.; Leuchs, B.; Aprahamian, M.; Rommelaere, J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. *Int. J. Cancer* **2008**, *122*, 2880–2884. [CrossRef] [PubMed]

43. Bodendorf, U.; Cziepluch, C.; Jauniaux, J.C.; Rommelaere, J.; Salomé, N. Nuclear export factor CRM1 interacts with nonstructural proteins NS2 from parvovirus minute virus of mice. *J. Virol.* **1999**, *73*, 7769–7779. [CrossRef] [PubMed]

44. López-Bueno, A.; Mateu, M.G.; Almendral, J.M. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. *J. Virol.* **2003**, *77*, 2701–2708. [CrossRef]

45. Ghita, L.; Breitkopf, V.; Mulenge, F.; Pavlou, A.; Gern, O.L.; Durán, V.; Prajeeth, C.K.; Kohls, M.; Jung, K.; Stangel, M.; et al. Sequential MAVS and MyD88/TRIF signaling triggers anti-viral responses of tick-borne encephalitis virus-infected murine astrocytes. *J. Neurosci. Res.* **2021**, *99*, 2478–2492. [CrossRef]

46. Nilausen, K.; Green, H. Reversible arrest of growth in G1 of an established fibroblast line (3T3). *Exp. Cell Res.* **1965**, *40*, 166–168. [CrossRef]

47. Zolotukhin, S.; Byrne, B.J.; Mason, E.; Zolotukhin, I.; Potter, M.; Chesnut, K.; Summerford, C.; Samulski, R.J.; Muzyczka, N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther.* **1999**, *6*, 973–985. [CrossRef]

48. Wilden, H.; Fournier, P.; Zawatzky, R.; Schirrmacher, V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. *Int. J. Oncol.* **2009**, *34*, 971–982. [CrossRef]

49. Daeffler, L.; Hörlein, R.; Rommelaere, J.; Nüesch, J.P.F. Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region. *J. Virol.* **2003**, *77*, 12466–12478. [CrossRef]

50. Schirrmacher, V.; van Gool, S.; Stuecker, W. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. *Biomedicines* **2019**, *7*, 66. [CrossRef]

51. Schirrmacher, V. Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus. *Biomedicines* **2022**, *10*, 562. [CrossRef] [PubMed]

52. Kowalinski, E.; Lunardi, T.; McCarthy, A.A.; Louber, J.; Brunel, J.; Grigorov, B.; Gerlier, D.; Cusack, S. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. *Cell* **2011**, *147*, 423–435. [CrossRef] [PubMed]

53. Lu, C.; Xu, H.; Ranjith-Kumar, C.T.; Brooks, M.T.; Hou, T.Y.; Hu, F.; Herr, A.B.; Strong, R.K.; Kao, C.C.; Li, P. The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. *Structure* **2010**, *18*, 1032–1043. [CrossRef] [PubMed]

54. Mattei, L.M.; Cotmore, S.F.; Tattersall, P.; Iwasaki, A. Parvovirus evades interferon-dependent viral control in primary mouse embryonic fibroblasts. *Virology* **2013**, *442*, 20–27. [CrossRef] [PubMed]

55. Cotmore, S.F.; Agbandje-McKenna, M.; Canuti, M.; Chiorini, J.A.; Eis-Hubinger, A.-M.; Hughes, J.; Mietzsch, M.; Modha, S.; Ogliastro, M.; Pénzes, J.J.; et al. ICTV Virus Taxonomy Profile: Parvoviridae. *J. Gen. Virol.* **2019**, *100*, 367–368. [CrossRef]
56. Wang, Z.; Shen, W.; Cheng, F.; Deng, X.; Engelhardt, J.F.; Yan, Z.; Qiu, J. Parvovirus Expresses a Small Noncoding RNA That Plays an Essential Role in Virus Replication. *J. Virol.* **2017**, *91*, e02375-16. [CrossRef]

57. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* **2003**, *31*, 3406-3415.
[CrossRef]

58. Buijs, P.; van Nieuwkoop, S.; Vaes, V.; Fouchier, R.; van Eijck, C.; van den Hoogen, B. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. *Viruses* **2015**, *7*, 2980-2998. [CrossRef]

59. Mattei, L.M.; Cotmore, S.F.; Li, L.; Tattersall, P.; Iwasaki, A. Toll-like receptor 9 in plasmacytoid dendritic cells fails to detect parvoviruses. *J. Virol.* **2013**, *87*, 3605-3608. [CrossRef]

60. Paglino, J.C.; Andres, W.; van den Pol, A.N. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. *J. Virol.* **2014**, *88*, 4932-4942. [CrossRef]

61. Rostovsky, I.; Davis, C. Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice. *J. Virol.* **2015**, *89*, 2182-2191. [CrossRef] [PubMed]

62. Loew, L.; Goonawardane, N.; Ratcliff, J.; Nguyen, D.; Simmonds, P. Use of a small DNA virus model to investigate mechanisms of CpG dinucleotide-induced attenuation of virus replication. *J. Gen. Virol.* **2020**, *101*, 1202-1218. [CrossRef] [PubMed]

63. Panne, D. The enhanceosome. *Curr. Opin. Struct. Biol.* **2008**, *18*, 236-242. [CrossRef] [PubMed]

64. Kang, H.; Liu, D.; Tian, J.; Hu, X.; Zhang, X.; Yin, H.; Wu, H.; Liu, C.; Guo, D.; Li, Z.; et al. Feline Panleucopenia Virus NS2 Suppresses the Host IFN-β Induction by Disrupting the Interaction between TBK1 and STING. *Viruses* **2017**, *9*, 23. [CrossRef] [PubMed]

65. Runde, A.P.; Mack, R.; Breslin S.J., P.; Zhang, J. The role of TBK1 in cancer pathogenesis and anticancer immunity. *J. Exp. Clin. Cancer Res. CR* **2022**, *41*, 135. [CrossRef]

66. Langer, S.; Hammer, C.; Hopfensperger, K.; Klein, L.; Hotter, D.; De Jesus, P.D.; Herbert, K.M.; Pache, L.; Smith, N.; van der Merwe, J.A.; et al. HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses. *eLife* **2019**, *8*, e41930. [CrossRef]

67. Irie, T.; Nagata, N.; Igarashi, T.; Okamoto, I.; Sakaguchi, T. Conserved charged amino acids within Sendai virus C protein play multiple roles in the evasion of innate immune responses. *PLoS ONE* **2010**, *5*, 10719. [CrossRef]

68. Zandi, M.; Shafaati, M.; Kalantar-Neyestanaki, D.; Pourghadamyari, H.; Fani, M.; Soltani, S.; Kaleji, H.; Abbasi, S. The role of SARS-CoV-2 accessory proteins in immune evasion. *Biomed. Pharmacother. Biomed. Pharmacother.* **2022**, *156*, 113889. [CrossRef]

69. Tal, S.; Mincberg, M.; Rostovsky, I.; Rommelaere, J.; Salome, N.; Davis, C. The Minute Virus of Mice NS2 proteins are not essential for productive infection of embryonic murine cells in utero. *Virology* **2014**, *468-470*, 631-636. [CrossRef]

70. Mihaylov, I.S.; Cotmore, S.F.; Tattersall, P. Complementation for an essential ancillary non-structural protein function across parvovirus genera. *Virology* **2014**, *468-470*, 226-237. [CrossRef]

71. Zhuandi, G.; Zhaofang, Y.; Dianyu, L.; Mengyuan, P.; Suocheng, W. Immune escape of bovine parvovirus by VP1 inhibiting IFN-β production through the RIG-I-like receptor pathway. *Int. Microbiol. Off. J. Span. Soc. Microbiol.* **2023**, 1-8. [CrossRef] [PubMed]

72. Wang, D.; Yuan, W.; Davis, I.; Parrish, C.R. Nonstructural protein-2 and the replication of canine parvovirus. *Virology* **1998**, *240*, 273-281. [CrossRef] [PubMed]

73. Hoelzer, K.; Shackelton, L.A.; Holmes, E.C.; Parrish, C.R. Within-Host Genetic Diversity of Endemic and Emerging Parvoviruses of Dogs and Cats. *J. Virol.* **2008**, *82*, 11096-11105. [CrossRef] [PubMed]

74. Gentili, M.; Lahaye, X.; Nadalin, F.; Nader, G.F.P.; Puig Lombardi, E.; Herve, S.; De Silva, N.S.; Rookhuizen, D.C.; Zueva, E.; Goudot, C.; et al. The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. *Cell Rep.* **2019**, *26*, 2377-2393. [CrossRef]

75. Ventoso, I.; Berlanga, J.J.; Almendral, J.M. Translation control by protein kinase R restricts minute virus of mice infection: Role in parvovirus oncolysis. *J. Virol.* **2010**, *84*, 5043-5051. [CrossRef]

76. Gil-Ranedo, J.; Gallego-García, C.; Almendral, J.M. Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. *Cell Rep.* **2021**, *36*, 109673. [CrossRef]

77. Son, K.-N.; Liang, Z.; Lipton, H.L. Double-Stranded RNA Is Detected by Immunofluorescence Analysis in RNA and DNA Virus Infections, Including Those by Negative-Stranded RNA Viruses. *J. Virol.* **2015**, *89*, 9383-9392. [CrossRef]

78. Dzananovic, E.; Patel, T.R.; Chojnowski, G.; Boniecki, M.J.; Deo, S.; McEleney, K.; Harding, S.E.; Bujnicki, J.M.; McKenna, S.A. Solution conformation of adenovirus virus associated RNA-I and its interaction with PKR. *J. Struct. Biol.* **2014**, *185*, 48-57. [CrossRef]

79. Cesaro, T.; Michiels, T. Inhibition of PKR by Viruses. *Front. Microbiol.* **2021**, *12*, 757238. [CrossRef]

80. Hur, S. Double-Stranded RNA Sensors and Modulators in Innate Immunity. *Annu. Rev. Immunol.* **2019**, *37*, 349-375. [CrossRef]

81. Hall, A.E.; Turnbull, C.; Dalmay, T. Y RNAs: Recent developments. *Biomol. Concepts* **2013**, *4*, 103-110. [CrossRef] [PubMed]

82. Vabret, N.; Najburg, V.; Solovyov, A.; Gopal, R.; McClain, C.; Šulc, P.; Balan, S.; Rahou, Y.; Beauclair, G.; Chazal, M.; et al. Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1. *iScience* **2022**, *25*, 104599. [CrossRef] [PubMed]

83. Cao, L.; Liu, S.; Li, Y.; Yang, G.; Luo, Y.; Li, S.; Du, H.; Zhao, Y.; Wang, D.; Chen, J.; et al. The Nuclear Matrix Protein SAFA Surveils Viral RNA and Facilitates Immunity by Activating Antiviral Enhancers and Super-enhancers. *Cell Host Microbe* **2019**, *26*, 369-384. [CrossRef] [PubMed]
56. Wang, Z.; Shen, W.; Cheng, F.; Deng, X.; Engelhardt, J.F.; Yan, Z.; Qiu, J. Parvovirus Expresses a Small Noncoding RNA That Plays an Essential Role in Virus Replication. *J. Virol.* **2017**, *91*, e02375-16. [CrossRef]

57. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* **2003**, *31*, 3406–3415. [CrossRef]

58. Buijs, P.; van Nieuwkoop, S.; Vaes, V.; Fouchier, R.; van Eijck, C.; van den Hoogen, B. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. *Viruses* **2015**, *7*, 2980–2998. [CrossRef]

59. Mattei, L.M.; Cotmore, S.F.; Li, L.; Tattersall, P.; Iwasaki, A. Toll-like receptor 9 in plasmacytoid dendritic cells fails to detect parvoviruses. *J. Virol.* **2013**, *87*, 3605–3608. [CrossRef]

60. Paglino, J.C.; Andres, W.; van den Pol, A.N. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. *J. Virol.* **2014**, *88*, 4932–4942. [CrossRef]

61. Rostovsky, I.; Davis, C. Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice. *J. Virol.* **2015**, *89*, 2182–2191. [CrossRef] [PubMed]

62. Loew, L.; Goonawardane, N.; Ratcliff, J.; Nguyen, D.; Simmonds, P. Use of a small DNA virus model to investigate mechanisms of CpG dinucleotide-induced attenuation of virus replication. *J. Gen. Virol.* **2020**, *101*, 1202–1218. [CrossRef] [PubMed]

63. Panne, D. The enhanceosome. *Curr. Opin. Struct. Biol.* **2008**, *18*, 236–242. [CrossRef] [PubMed]

64. Kang, H.; Liu, D.; Tian, J.; Hu, X.; Zhang, X.; Yin, H.; Wu, H.; Liu, C.; Guo, D.; Li, Z.; et al. Feline Panleucopenia Virus NS2 Suppresses the Host IFN-β Induction by Disrupting the Interaction between TBK1 and STING. *Viruses* **2017**, *9*, 23. [CrossRef] [PubMed]

65. Runde, A.P.; Mack, R.; Breslin S.J., P.; Zhang, J. The role of TBK1 in cancer pathogenesis and anticancer immunity. *J. Exp. Clin. Cancer Res. CR* **2022**, *41*, 135. [CrossRef]

66. Langer, S.; Hammer, C.; Hopfensperger, K.; Klein, L.; Hotter, D.; De Jesus, P.D.; Herbert, K.M.; Pache, L.; Smith, N.; van der Merwe, J.A.; et al. HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses. *eLife* **2019**, *8*, e41930. [CrossRef]

67. Irie, T.; Nagata, N.; Igarashi, T.; Okamoto, I.; Sakaguchi, T. Conserved charged amino acids within Sendai virus C protein play multiple roles in the evasion of innate immune responses. *PLoS ONE* **2010**, *5*, 10719. [CrossRef]

68. Zandi, M.; Shafaati, M.; Kalantar-Neyestanaki, D.; Pourghadamyari, H.; Fani, M.; Soltani, S.; Kaleji, H.; Abbasi, S. The role of SARS-CoV-2 accessory proteins in immune evasion. *Biomed. Pharmacother. Biomed. Pharmacother.* **2022**, *156*, 113889. [CrossRef]

69. Tal, S.; Mincberg, M.; Rostovsky, I.; Rommelaere, J.; Salome, N.; Davis, C. The Minute Virus of Mice NS2 proteins are not essential for productive infection of embryonic murine cells in utero. *Virology* **2014**, *468–470*, 631–636. [CrossRef]

70. Mihaylov, I.S.; Cotmore, S.F.; Tattersall, P. Complementation for an essential ancillary non-structural protein function across parvovirus genera. *Virology* **2014**, *468–470*, 226–237. [CrossRef]

71. Zhuandi, G.; Zhaofang, Y.; Dianyu, L.; Mengyuan, P.; Suocheng, W. Immune escape of bovine parvovirus by VP1 inhibiting IFN-β production through the RIG-I-like receptor pathway. *Int. Microbiol. Off. J. Span. Soc. Microbiol.* **2023**, 1–8. [CrossRef] [PubMed]

72. Wang, D.; Yuan, W.; Davis, I.; Parrish, C.R. Nonstructural protein-2 and the replication of canine parvovirus. *Virology* **1998**, *240*, 273–281. [CrossRef] [PubMed]

73. Hoelzer, K.; Shackelton, L.A.; Holmes, E.C.; Parrish, C.R. Within-Host Genetic Diversity of Endemic and Emerging Parvoviruses of Dogs and Cats. *J. Virol.* **2008**, *82*, 11096–11105. [CrossRef] [PubMed]

74. Gentili, M.; Lahaye, X.; Nadalin, F.; Nader, G.F.P.; Puig Lombardi, E.; Herve, S.; De Silva, N.S.; Rookhuizen, D.C.; Zueva, E.; Goudot, C.; et al. The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. *Cell Rep.* **2019**, *26*, 2377–2393. [CrossRef]

75. Ventoso, I.; Berlanga, J.J.; Almendral, J.M. Translation control by protein kinase R restricts minute virus of mice infection: Role in parvovirus oncolysis. *J. Virol.* **2010**, *84*, 5043–5051. [CrossRef]

76. Gil-Ranedo, J.; Gallego-García, C.; Almendral, J.M. Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. *Cell Rep.* **2021**, *36*, 109673. [CrossRef]

77. Son, K.-N.; Liang, Z.; Lipton, H.L. Double-Stranded RNA Is Detected by Immunofluorescence Analysis in RNA and DNA Virus Infections, Including Those by Negative-Stranded RNA Viruses. *J. Virol.* **2015**, *89*, 9383–9392. [CrossRef]

78. Dzananovic, E.; Patel, T.R.; Chojnowski, G.; Boniecki, M.J.; Deo, S.; McEleney, K.; Harding, S.E.; Bujnicki, J.M.; McKenna, S.A. Solution conformation of adenovirus virus associated RNA-I and its interaction with PKR. *J. Struct. Biol.* **2014**, *185*, 48–57. [CrossRef]

79. Cesaro, T.; Michiels, T. Inhibition of PKR by Viruses. *Front. Microbiol.* **2021**, *12*, 757238. [CrossRef]

80. Hur, S. Double-Stranded RNA Sensors and Modulators in Innate Immunity. *Annu. Rev. Immunol.* **2019**, *37*, 349–375. [CrossRef]

81. Hall, A.E.; Turnbull, C.; Dalmay, T. Y RNAs: Recent developments. *Biomol. Concepts* **2013**, *4*, 103–110. [CrossRef] [PubMed]

82. Vabret, N.; Najburg, V.; Solovyov, A.; Gopal, R.; McClain, C.; Šulc, P.; Balan, S.; Rahou, Y.; Beauclair, G.; Chazal, M.; et al. Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1. *iScience* **2022**, *25*, 104599. [CrossRef] [PubMed]

83. Cao, L.; Liu, S.; Li, Y.; Yang, G.; Luo, Y.; Li, S.; Du, H.; Zhao, Y.; Wang, D.; Chen, J.; et al. The Nuclear Matrix Protein SAFA Surveils Viral RNA and Facilitates Immunity by Activating Antiviral Enhancers and Super-enhancers. *Cell Host Microbe* **2019**, *26*, 369–384. [CrossRef] [PubMed]
84. Harrington, K.; Freeman, D.J.; Kelly, B.; Harper, J.; Soria, J.-C. Optimizing oncolytic virotherapy in cancer treatment. *Nat. Rev. Drug Discov.* **2019**, *18*, 689–706. [CrossRef]

85. Jamieson, T.R.; Poutou, J.; Ilkow, C.S. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. *Cytokine Growth Factor Rev.* **2020**, *56*, 102–114. [CrossRef]

86. Sprooten, J.; Agostinis, P.; Garg, A.D. Type I interferons and dendritic cells in cancer immunotherapy. *Int. Rev. Cell Mol. Biol.* **2019**, *348*, 217–262. [CrossRef]

87. Liang, Y.; Hannan, R.; Fu, Y.-X. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2021**, *27*, 3818–3824. [CrossRef]

88. Vitale, G.; van Eijck, C.H.J.; van Koetsveld Ing, P.M.; Erdmann, J.I.; Speel, E.J.M.; van der Wansem Ing, K.; Mooij, D.M.; Colao, A.; Lombardi, G.; Croze, E.; et al. Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related receptors. *Ann. Surg.* **2007**, *246*, 259–268. [CrossRef]

89. Zhang, F.; Manna, S.; Pop, L.M.; Chen, Z.J.; Fu, Y.-X.; Hannan, R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. *Semin. Radiat. Oncol.* **2020**, *30*, 129–138. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
84. Harrington, K.; Freeman, D.J.; Kelly, B.; Harper, J.; Soria, J.-C. Optimizing oncolytic virotherapy in cancer treatment. *Nat. Rev. Drug Discov.* **2019**, *18*, 689–706. [CrossRef]

85. Jamieson, T.R.; Poutou, J.; Ilkow, C.S. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. *Cytokine Growth Factor Rev.* **2020**, *56*, 102–114. [CrossRef]

86. Sprooten, J.; Agostinis, P.; Garg, A.D. Type I interferons and dendritic cells in cancer immunotherapy. *Int. Rev. Cell Mol. Biol.* **2019**, *348*, 217–262. [CrossRef]

87. Liang, Y.; Hannan, R.; Fu, Y.-X. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2021**, *27*, 3818–3824. [CrossRef]

88. Vitale, G.; van Eijck, C.H.J.; van Koetsveld Ing, P.M.; Erdmann, J.I.; Speel, E.J.M.; van der Wansem Ing, K.; Mooij, D.M.; Colao, A.; Lombardi, G.; Croze, E.; et al. Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related receptors. *Ann. Surg.* **2007**, *246*, 259–268. [CrossRef]

89. Zhang, F.; Manna, S.; Pop, L.M.; Chen, Z.J.; Fu, Y.-X.; Hannan, R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. *Semin. Radiat. Oncol.* **2020**, *30*, 129–138. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.